IL12B (rs3213094) gene variant in people with psoriasis
Evaluation of IL 12B Genetic Polymorphism (rs3213094) in Patient With Psoriasis and Psoriatic Arthritis in Response to Humira
NA · South Valley University · NCT07128472
This test looks at whether a specific IL12B gene change (rs3213094) is linked to how people with moderate-to-severe psoriasis respond to Humira.
Quick facts
| Phase | NA |
|---|---|
| Study type | Interventional |
| Enrollment | 40 (estimated) |
| Ages | 18 Years to 70 Years |
| Sex | All |
| Sponsor | South Valley University (other) |
| Drugs / interventions | adalimumab |
| Locations | 1 site (Qina) |
| Trial ID | NCT07128472 on ClinicalTrials.gov |
What this trial studies
This interventional study enrolls people with clinically diagnosed moderate-to-severe psoriasis who are being treated with Humira and genotypes them for the IL12B rs3213094 polymorphism. Participants receive standard Humira therapy while investigators collect clinical outcome measures, including PASI scores and assessments for psoriatic arthritis. The study aims to correlate the genetic variant with treatment response and disease features. Data will be analyzed to see if the IL12B variant predicts better or worse outcomes on Humira.
Who should consider this trial
Good fit: Adults with clinically diagnosed psoriasis for at least six months, severe disease (PASI >10 and >10% BSA) and who are receiving Humira are the intended participants.
Not a fit: People with other autoimmune or inflammatory conditions, active infections, pregnancy or lactation, known immune genetic disorders, contraindications to Humira, or those not on Humira are excluded and unlikely to benefit from the findings.
Why it matters
Potential benefit: If successful, this could help personalize psoriasis treatment by identifying patients more likely to respond to Humira based on their IL12B genotype.
How similar studies have performed: Genetic studies have linked IL12B variants to psoriasis risk, but using rs3213094 specifically to predict Humira response is relatively limited and not yet well established.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: \- Patients having psoriasis diagnosed clinically for at least 6 months and who have a severity grade of severe, defined as a Psoriasis Area and Severity Index (PASI) score greater than 10, and involvement of greater than 10% of the body surface area (BSA) with psoriatic arthritis. Exclusion Criteria: * Patients with other autoimmune or inflammatory conditions (e.g., rheumatoid arthritis, lupus). * Pregnancy and lactation. * Patients currently undergoing any treatment other than Humira. * Patients with known genetic disorders affect immune system function. * Patients were undergoing any treatment other than Humira in the last 6 months. * Patients with active infections, including tuberculosis or chronic viral infections (e.g., hepatitis B or C, HIV). * Patients with contraindication to Humira. * Renal \&Vascular diseases
Where this trial is running
Qina
- Qina University hospital, South Valley University Hospital — Qina, Egypt (RECRUITING)
Study contacts
- Principal investigator: Mohamed Hosny Hassan, Professor — Medical Biochemistry Department,Qena Faculty of Medicine,south valley university
- Study coordinator: Alaa Ahmed Saad Ali Aweida, MSc
- Email: alaaahmed201666@gmail.com
- Phone: +201119814470
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Psoriasis